% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • pfw2141 pfw2141 Jan 2, 2013 7:35 AM Flag

    Up today...........

    Aeterna Zentaris (NASDAQ:AEZS) has reached an agreement with the FDA on a Special Protocol Assessment for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The acord states that the proposed trial protocol design, clinical endpoints and planned analyses are all acceptable to the FDA in support of a regulatory submission.

    Sentiment: Strong Buy

11.06-0.37(-3.24%)Nov 27 1:00 PMEST